Millions of Medicare beneficiaries might see adjustments in how laboratory tests are reimbursed. The Centers for Medicare & Medicaid Services (CMS) has released preliminary payment rates for 2027 regarding clinical lab services. The rates are determined based on recent private insurer data collected under the Protecting Access to Medicare Act (PAMA). This law seeks to align Medicare reimbursements with market prices.
According to CMS, Medicare has been paying around 16 percent more than private insurers for lab services. The proposed changes are expected to save taxpayers approximately $1 billion each year. Dr. Mehmet Oz, CMS Administrator, noted, ‘Taxpayers and Medicare patients have been paying excessive rates for years. With help from Congress, CMS is working to ensure Medicare payments align more closely with private insurer rates.’
By releasing this preliminary information, we are providing greater transparency into the actual market rates for laboratory services, rooting out waste, and supporting better-informed pricing decisions across the healthcare system, including Medicaid and Affordable Care Act Exchanges.
Why It Matters
Lab tests play a crucial role in healthcare, involving procedures from routine blood work to advanced genetic diagnostics. Though these changes don’t directly affect what Medicare beneficiaries pay out-of-pocket, they may influence lab revenues. This, in turn, impacts the larger debate over Medicare’s payment accuracy concerning the cost of testing services.
CMS claims these updated rates will better align with market realities, reducing excessive spending. However, some lab groups argue that drastic reimbursement cuts might limit patient access to testing, particularly in underserved regions.
What To Know
CMS released preliminary private-payor rates for diagnostic tests under the Clinical Laboratory Fee Schedule (CLFS). This system is used by Medicare to pay for services like blood tests, urinalysis, and molecular diagnostics. The largest potential reductions identified include genomic sequencing (-23 percent) and molecular pathology (-22 percent). Chemistry testing, vital for many Medicare beneficiaries, shows a potential reduction of 16 percent.
This is the second data collection cycle for most lab tests under PAMA since its 2014 enactment. Congress has previously delayed this procedure but requires new reporting in 2026. CMS will implement reductions gradually, ensuring no single year exceeds a 15 percent decrease until 2029.
Kevin Thompson, CEO of 9i Capital Group, commented, ‘Aligning the new payment schedule with private insurance data allows for more consistent industry pricing.’
Industry Pushback
Quest Diagnostics criticized the preliminary rates, stating they highlight flaws in PAMA’s rate-setting process. They urged Congress to pass the RESULTS Act to address these flaws by implementing a broader reporting framework. Over 130 members of Congress and 70 organizations support this reform to fortify the laboratory system’s future.
A survey commissioned by Quest showed that 96 percent of voters value diagnostic testing for personal or familial care. Also, 74 percent believe Congress should prevent payment cuts before impacting patients.
Thompson added, ‘Private insurers often pay lower costs compared to Medicare, which must cover a wider range of services. Understanding Medicare’s obligation across all providers and medically necessary services is essential.’
The American Clinical Laboratory Association reports nearly 1,200 lab tests could face reductions, including many reaching the 15 percent annual cut limit in 2027.
What Happens Next
The public can comment on these preliminary rates over the next 30 days. Afterward, CMS will review inputs before finalizing the 2027 Clinical Laboratory Fee Schedule by November. Long-term, concerns persist about a potential shift toward Medicare functioning more like Medicare Advantage, with increased use of prior authorization and coverage restrictions.
Thompson notes, ‘If reimbursements continue to decline, costs might emerge elsewhere in the healthcare system or affect beneficiary access to services.’